Changes to This Summary (02 / 19 / 2013)
Added text to state that in a meta-analysis of 2,586 patients with follicular lymphoma, nine randomized clinical trials compared rituximab maintenance with no maintenance and showed improved overall survival (OS) for rituximab maintenance in previously treated patients (cited Vidal et al. as reference 56 and level of evidence: 1iiA).
Added Al Khabori et al. as reference 66.
Added text to the list of treatment options under clinical evaluation to include ofatumumab, a human anti-CD20 monoclonal antibody (cited Czuczman et al. as reference 71) and short-course low-dose, palliative radiation therapy (cited Chan et al. and Rossier et al. as references 72 and 73, respectively).
Treatment for Aggressive, Stage I and Contiguous Stage II Adult NHL
Revised text to state that with a median follow-up of 72 months, the event-free survival favored R-CHOP given every 2 weeks for six or eight cycles. Also revised statistics about OS favoring R-CHOP for only six cycles because of increased toxicity in the eight-cycle arm (cited Pfreundschuh et al. as reference 8).
Treatment for Aggressive, Noncontiguous Stage II/III/IV Adult NHL
Added text to state that a trial of 380 patients younger than 60 years with diffuse large B-cell lymphoma and an age-adjusted International Prognostic Index rating of 1 randomized treatment to ACVBP + rituximab versus CHOP + rituximab; with a median follow-up of 44 months, 3-year OS favored R-ACVBP (cited Récher et al. as reference 7 and level of evidence: 1iiA).
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.